Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: The end of the affair with gene therapy

This article was originally published in Scrip

Executive Summary

The End of the Affair, a 1951 novel by Graham Greene, depicts some of the worst human emotions that can accompany the ending of a relationship, and then after a break of two years, the re-ignition of those emotions in an investigative post-mortem. Way back at the start of this century I invested in a gene therapy company. Although the inevitable end of the affair caused me some heartache, unlike the principal characters in Mr Greene's classic novel I found it a valuable cathartic learning experience to have lost some money in this unproven area of biotechnology.

You may also be interested in...



Stockwatch: The Pandemic’s Effects On Big Pharma – A Year In

Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.

Stockwatch: Oncology Dynamics Underscore Roche And AstraZeneca’s Contrasting Fortunes

Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.

Stockwatch: Lilly’s Fourth Quarter − Pandemic Benefits And Challenges

Lilly’s fourth-quarter results included windfalls, not just from the pandemic but from seasonal wholesaler buying patterns that were intensified by the pandemic and raise a high bar for subsequent quarters.

Related Companies

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel